We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche Won’t Give Up on Actemra for Treating COVID-19 Despite Trial’s Failure
Roche Won’t Give Up on Actemra for Treating COVID-19 Despite Trial’s Failure
Roche’s rheumatoid arthritis blockbuster Actemra (tocilizumab) showed no benefit for hospitalized COVID-19 patients in a phase 3 trial, but the company still has high hopes for the drug as a potential treatment for COVID-19 infections.